Momenta Pharmaceuticals Inc (MNTA)

11.49
0.15 1.40
NASDAQ : Health Care
Prev Close 11.34
Open 11.39
Day Low/High 11.39 / 11.58
52 Wk Low/High 7.86 / 23.62
Volume 28.20K
Avg Volume 492.50K
Exchange NASDAQ
Shares Outstanding 69.50M
Market Cap 790.87M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Visium Hedge Fund Partner Charged in Insider Trading Case

Visium Hedge Fund Partner Charged in Insider Trading Case

After a Supreme Court setback to the federal crackdown on insider trading, U.S. Attorney Preet Bharara signals his intent to forge ahead with new indictments reminiscent of the SAC case.

Momenta Pharmaceuticals Announces Presentation Of Final Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer At ASCO

Momenta Pharmaceuticals Announces Presentation Of Final Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer At ASCO

Novel oncology candidate necuparanib had favorable tolerability and encouraging signals of activity in Phase 1 study

Insider Trading Alert - STS, RRGB And MNTA Traded By Insiders

Insider Trading Alert - STS, RRGB And MNTA Traded By Insiders

Stocks with insider trader activity include STS, RRGB and MNTA

Momenta Pharmaceuticals (MNTA) Is Strong On High Volume Today

Momenta Pharmaceuticals (MNTA) Is Strong On High Volume Today

Trade-Ideas LLC identified Momenta Pharmaceuticals (MNTA) as a strong on high relative volume candidate

6 Biotech Stocks Under $10 to Trade for Big Breakouts

6 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

First Week Of MNTA May 20th Options Trading

First Week Of MNTA May 20th Options Trading

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new May 20th contracts and identified one put and one call contract of particular interest.

RSI Alert: Momenta Pharmaceuticals (MNTA) Now Oversold

RSI Alert: Momenta Pharmaceuticals (MNTA) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Insider Trading Alert - GST, MNTA And ZEN Traded By Insiders

Insider Trading Alert - GST, MNTA And ZEN Traded By Insiders

Stocks with insider trader activity include GST, MNTA and ZEN

Commit To Buy Momenta Pharmaceuticals At $8, Earn 13.3% Annualized Using Options

Commit To Buy Momenta Pharmaceuticals At $8, Earn 13.3% Annualized Using Options

Investors considering a purchase of Momenta Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $8 strike, which has a bid at the time of this writing of 60 cents.

Trade-Ideas: Momenta Pharmaceuticals (MNTA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Momenta Pharmaceuticals (MNTA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Momenta Pharmaceuticals (MNTA) as a strong on high relative volume candidate

Oversold Conditions For Momenta Pharmaceuticals (MNTA)

Oversold Conditions For Momenta Pharmaceuticals (MNTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Mylan Announces Worldwide Collaboration With Momenta To Jointly Develop And Commercialize Six Biosimilar Products

Mylan Announces Worldwide Collaboration With Momenta To Jointly Develop And Commercialize Six Biosimilar Products

Partnership Builds on Successful Existing Collaboration with Biocon and Positions Mylan as a World Leader in Biosimilars

Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan To Jointly Develop And Commercialize Six Biosimilar Products

Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan To Jointly Develop And Commercialize Six Biosimilar Products

Momenta to Host a Conference Call for Investors Today at 10 AM ET